Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: A scenario with a favorable Markman II ...
If there is a favorable Markman I would like to see a trial, but I doubt Leckrone will go that far. So that leaves a settlement. Hopefully PTSC will get a solid settlement number during the negotiations. Now that leaves the PR to announce said settlement. The ONLY PR that will be acceptable that could indicate future licenses is if there is a dividend announcement in the same PR announcing the settlement. Otherwise it means we got enough to barely cover our costs and then the "wait til the SEC filing" crowd will jump in.
Share
New Message
Please login to post a reply